Fulgent Genetics (FLGT) Competitors $19.12 -0.15 (-0.78%) Closing price 04:00 PM EasternExtended Trading$19.11 -0.01 (-0.03%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FLGT vs. VCYT, ADUS, PACS, ARDT, LFST, PGNY, GRAL, NHC, TDOC, and VRDNShould you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Veracyte (VCYT), Addus HomeCare (ADUS), PACS Group (PACS), Ardent Health (ARDT), LifeStance Health Group (LFST), Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. Fulgent Genetics vs. Its Competitors Veracyte Addus HomeCare PACS Group Ardent Health LifeStance Health Group Progyny GRAIL National HealthCare Teladoc Health Viridian Therapeutics Veracyte (NASDAQ:VCYT) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has higher valuation and earnings, VCYT or FLGT? Veracyte has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M4.68$24.14M$0.4165.00Fulgent Genetics$292.45M1.99-$42.71M-$1.33-14.38 Which has more volatility & risk, VCYT or FLGT? Veracyte has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Is VCYT or FLGT more profitable? Veracyte has a net margin of 7.13% compared to Fulgent Genetics' net margin of -13.94%. Veracyte's return on equity of 6.14% beat Fulgent Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Veracyte7.13% 6.14% 5.60% Fulgent Genetics -13.94%-2.19%-2.02% Do analysts prefer VCYT or FLGT? Veracyte presently has a consensus price target of $40.90, suggesting a potential upside of 53.47%. Fulgent Genetics has a consensus price target of $24.00, suggesting a potential upside of 25.52%. Given Veracyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veracyte is more favorable than Fulgent Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Fulgent Genetics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to VCYT or FLGT? In the previous week, Veracyte had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Veracyte and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.19 beat Veracyte's score of 0.89 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of VCYT or FLGT? 48.1% of Fulgent Genetics shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryVeracyte beats Fulgent Genetics on 13 of the 16 factors compared between the two stocks. Get Fulgent Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLGT vs. The Competition Export to ExcelMetricFulgent GeneticsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$582.09M$2.00B$5.54B$9.14BDividend YieldN/AN/A5.01%4.00%P/E Ratio-14.3834.8628.6919.46Price / Sales1.9911.38373.1779.78Price / CashN/A54.0224.7227.47Price / Book0.528.508.255.58Net Income-$42.71M-$62.39M$3.19B$252.81M7 Day Performance-0.88%4.03%5.59%3.24%1 Month Performance-7.59%10.35%9.57%11.87%1 Year Performance-8.74%5.80%30.64%17.60% Fulgent Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLGTFulgent Genetics4.1277 of 5 stars$19.12-0.8%$24.00+25.5%-8.0%$582.09M$292.45M-14.381,313Positive NewsVCYTVeracyte3.5871 of 5 stars$26.34-4.3%$40.90+55.3%+19.0%$2.15B$445.76M64.25790ADUSAddus HomeCare4.979 of 5 stars$110.62-1.1%$142.57+28.9%-8.3%$2.06B$1.15B24.9749,703Positive NewsPACSPACS Group2.8093 of 5 stars$12.51-4.8%$34.29+174.1%-59.2%$2.00B$3.11B0.0032,433ARDTArdent Health3.3441 of 5 stars$13.34-0.4%$20.67+54.9%N/A$1.92B$5.97B8.1824,900Analyst DowngradeLFSTLifeStance Health Group3.0729 of 5 stars$4.68-2.3%$8.50+81.6%-15.4%$1.86B$1.25B-46.8010,218PGNYProgyny1.095 of 5 stars$21.450.0%$23.45+9.3%-19.8%$1.84B$1.17B37.63310Analyst RevisionGRALGRAIL0.6774 of 5 stars$44.85-4.0%$31.50-29.8%+175.0%$1.68B$125.60M-0.741,360NHCNational HealthCareN/A$104.23-3.9%N/A-14.6%$1.68B$1.37B13.0612,400TDOCTeladoc Health2.7966 of 5 stars$8.06-2.8%$9.60+19.1%-11.3%$1.45B$2.57B-1.365,500VRDNViridian Therapeutics3.1723 of 5 stars$15.89+1.4%$37.56+136.3%+22.7%$1.28B$300K-4.1350 Related Companies and Tools Related Companies VCYT Competitors ADUS Competitors PACS Competitors ARDT Competitors LFST Competitors PGNY Competitors GRAL Competitors NHC Competitors TDOC Competitors VRDN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLGT) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
